Home Newsfeeds JMP Securities Downgrades Boyd Gaming to Market Perform

JMP Securities Downgrades Boyd Gaming to Market Perform

JMP Securities analyst Jordan Bender downgrades Boyd Gaming (NYSE:BYD) from Market Outperform to Market Perform.

byBenzinga Newsdesk

December 12, 2022

1 minute read

JMP Securities analyst Jordan Bender downgrades Boyd Gaming (NYSE:BYD) from Market Outperform to Market Perform.

US Labor Board Slaps Complaint On Amazon For Bargaining Anomalies

By Anusuya Lahiri

July 13, 9:55 AM

On Wednesday, the National Labor Relations Board (NLRB) filed a complaint against Amazon.Com, Inc (NASDAQ: AMZN) for refusing to bargain with a

AMZN

Maximus Awarded Centers for Medicare & Medicaid Services Contract for Contact Center Operations Valued At $6.6B

By Michael Horton

September 1, 5:18 PM

Maximus (NYSE:MMS), a leading employer and provider of government services worldwide, today announced that it has been awarded a contract for a base period for transition plus nine (one year) option periods with a

MMS

Top 4 Materials Stocks That Could Blast Off In Q4

By Lisa Levin

October 25, 7:24 AM

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.

ABAT

News

2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies

By Benzinga Newsdesk

September 12, 6:55 AM

2seventy bio, Inc. (NASDAQ:TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and

TSVT

JMP Securities Downgrades Boyd Gaming to Market Perform

Related Posts

US Labor Board Slaps Complaint On Amazon For Bargaining Anomalies

Maximus Awarded Centers for Medicare & Medicaid Services Contract for Contact Center Operations Valued At $6.6B

Top 4 Materials Stocks That Could Blast Off In Q4

2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies